Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients

BACKGROUND: The 2020 National Comprehensive Cancer Network guidelines recommend neoadjuvant FOLFIRINOX or neoadjuvant gemcitabine plus nab‐paclitaxel (G‐nP) for borderline resectable/locally advanced pancreatic ductal adenocarcinoma (BR/LA PDAC). AIM: The purpose of our study was to compare treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Ingram, Myles A., Lauren, Brianna N., Pumpalova, Yoanna, Park, Jiheum, Lim, Francesca, Bates, Susan E., Kastrinos, Fay, Manji, Gulam A., Kong, Chung Yin, Hur, Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458514/
https://www.ncbi.nlm.nih.gov/pubmed/35122419
http://dx.doi.org/10.1002/cnr2.1565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458514/
https://www.ncbi.nlm.nih.gov/pubmed/35122419
http://dx.doi.org/10.1002/cnr2.1565

Ejemplares similares